Editors-in-Chief

  • Douglas R Galasko, University of California, San Diego
  • Todd E Golde, University of Florida
  • Philip Scheltens, VU University Medical Center

Society Affiliations

logo

Affiliated to Alzheimer's Disease International (ADI), London, United Kingdom

Alzheimer's Disease International is the international federation of national Alzheimer organisations and global voice for dementia, leading and unifying the dementia community to provide global solutions to a global epidemic.

Articles

There has been an error retrieving the data. Please try again.
  • Performance on a pattern separation task

    A pattern separation test in mild to moderate Alzheimer’s disease patients suggests a possible genetic link to poor hippocampal neurogenesis, with performance related to apolipoprotein ϵ4 status and cerebrospinal fluid amyloid-β42 levels.

    Alzheimer's Research & Therapy 2014, 6:20
  • TMEM106B reduction in AD brains

    Transmembrane glycoprotein TMEM106B is downregulated, and progranulin is upregulated, in Alzheimer’s disease (AD) brains compared to non-AD brains, suggesting TMEM106B may have a key role in AD pathogenesis.

    Alzheimer's Research & Therapy 2014, 6:17
  • A new target for immunotherapy

    Lannfelt and colleagues review previous and ongoing active and passive amyloid-beta immunotherapy programs at the clinical stage, discussing why BAN2401 is a promising therapeutic candidate in early Alzheimer’s disease and hopes for other new innovative therapies.

    Alzheimer's Research & Therapy 2014, 6:16
  • Amyloid-beta in lipid rafts

    Pharmacological manipulation of neurons in vitro by platelet-activating factor (PAF) antagonists significantly increases amyloid-beta42 degradation, supporting that PAF controls a cholesterol-sensitive pathway that affects the cellular localisation and fate of amyloid-beta42.

    Alzheimer's Research & Therapy 2014, 6:15
  • Aβ reduction criteria in the clinic

    Based on genetic, risk factor, clinical and preclinical studies, Toyn and Ahlijanian propose clinical trials need to lower amyloid-beta (Aβ) by a minimum of 25% to adequately test the amyloid hypothesis in Alzheimer's disease.

    Alzheimer's Research & Therapy 2014, 6:14
  • Protein recycling pathways in neurodegeneration

    Siddique and colleagues review the ubiquitin-proteasome or autophagy pathways whose dysfunction might contribute to the pathology of various neurodegenerative diseases, discussing how induction of these pathways may be a therapeutic strategy.

    Alzheimer's Research & Therapy 2014, 6:13
  • "Partners in dementia care" programme success

    A care coordination programme between community and health organisations for patients with Alzheimer's disease and their carers resulted in improvements in psychosocial function of people with dementia.

    Alzheimer's Research & Therapy 2014, 6:9
  • HDAC6 inhibitors in tauopathy therapeutics

    Histone deacetylase 6 (HDAC6) inhibition by tubastatin A improved memory and reduced total tau levels in a mouse model of tau deposition; supporting HDAC6 inhibitors as novel therapeutic agents against tau pathology.

    Alzheimer's Research & Therapy 2014, 6:12

Latest free review

The following review has recently become free to access:

Review

Alcohol-related dementia: an update of the evidence  

Nicole J Ridley, Brian Draper, Adrienne Withall

Alzheimer's Research & Therapy 2013, 5:3 (25 January 2013)

RSS

Comments

View more comments

2014-02_AlzR&T_Lewy-Body-Dementia-v3
Traumatic brain injury
Alzres Manuscript
2014_01_AlzR&T_Tau_special_series
Alzheimer's Research & Therapy on Twitter
2014_01_alzheimer_research_&_therapy_peripheral_biomarkers
Alzres Manuscript

Aims & scope

Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports. Although the primary focus is Alzheimer's dementia, the scope encompasses translational research into other neurodegenerative diseases.

Latest issue

Alzheimer's Research & Therapy Volume 6 Issue 1

The complete issue of Alzheimer's Research & Therapy Volume 6 Issue 1 is now available.

Article collections

View all article collections

Multimedia

The evolving field of traumatic brain injury

What do we currently know about chronic traumatic encephalopathy (CTE) and what are the most important questions in the field? Listen to a free podcast discussing this and more, as part of our special series on Traumatic Brain Injury.

Searching for biomarkers

As part of our special series on Peripheral Biomarkers, listen to a free podcast by Douglas Galasko about the advances and current issues in the search to identify blood biomarkers for Alzheimer's disease.

Submit a manuscript Sign up for article alerts Contact us

Email updates

Receive periodic news and updates relating to this journal straight to your inbox.

Indexed by

  • CAS
  • DOAJ
  • Embase
  • Journal Citation Reports/Science Edition
  • PubMed
  • PubMed Central
  • Science Citation Index Expanded
  • Scopus

View all

ISSN: 1758-9193